Thalidomide for nausea in pancreatic cancer patients
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding thalidomide to standard chemotherapy can help reduce nausea and vomiting in people with advanced pancreatic cancer. It is for patients who have not yet received any cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have been diagnosed with metastatic pancreatic adenocarcinoma (cancer that has spread).
- You have not had any prior cancer treatment for this disease.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
- You do not have active inflammation of the digestive tract, like pancreatitis or gallbladder infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a diabetes treatment to standard chemotherapy helps people with pancreatic cancer that has spread and who also have diabetes. It might improve how well the cancer is controlled and how you feel.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of chemotherapy drugs (NALIRIFOX given through a vein plus paclitaxel given directly into the abdomen) for people with pancreatic cancer that has spread to the lining of the belly but not to other organs. The goal is to see if this approach is safe and effective.
Hear when a new Pancreatic Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.